Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017

4 years ago
Discovery
In Focus

The good, the bad and the ug­ly for the top 15 spenders in the glob­al drug R&D busi­ness: 2018

4 years ago
R&D
Special

Bris­tol-My­ers of­fers some ea­ger­ly await­ed Check­mate-227 re­sults, but they're not chang­ing med­ical prac­tice -- yet

4 years ago
R&D

What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?

4 years ago
Financing

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017

4 years ago
Financing
Startups

The class of 2017's win­ners and losers: A year of 'non­stop sci­en­tif­ic achieve­ments' rais­es trou­bling is­sues

4 years ago
Pharma

Bio­phar­ma's top 10 over­seas cash hoards. And what kind of M&A spree would $171B buy?

4 years ago
Deals

The top 10 hit pa­rade of bio­phar­ma li­cens­ing deals for 2014-2017

4 years ago
Pharma

Who are the top 10 play­ers that dom­i­nate the can­cer drug mar­ket? And who's grow­ing fastest?

4 years ago
R&D
Pharma

In­sid­ers: The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

4 years ago

R&D trend #5: The top ex­ecs in biotech are rid­ing a boom — but there’s one big step left

4 years ago

Top trend #4: We’re com­ing to a tip­ping point on can­cer R&D, and it may not be pret­ty

4 years ago
R&D

The top 5 trends in biotech - #3: High val­u­a­tions for at­trac­tive biotechs are a durable symp­tom of a thriv­ing fi­nanc­ing are­na

4 years ago

How En­ter­prise cus­tomers can get End­points News in­to their Slack

4 years ago
Publisher's note

Top 5 bio­phar­ma trends: The long-await­ed bio­phar­ma rev­o­lu­tion in Chi­na has ar­rived — don’t lose out

4 years ago
China

The top 5 trends re­shap­ing bio­phar­ma starts with an R&D earth­quake

4 years ago
First page Previous page 78910